Main

March 05, 2008

FYI on healthcare

Bruce Patteson

OK, so it's hardly a secret that healthcare is in "challenging times."  The question is, are we faced with an insurmountable problem or the fact that we just haven't found the silver bullet?

On one hand, it's a gigantically tough nut to crack.  Premiums for family coverage have skyrocketed 78 percent since 2001, while wages have  gone up 19 percent. And telling you that "this may sting a bit" doesn't do much to prepare you for the pain. 

The much larger problem is that it's getting worse.  And though everyone from healthcare providers to hospitals to insurers are equally concerned about the trend, there's hardly agreement across the board about how to reverse it.  Or at least slow it down to sub-supersonic speeds.

To solve a challenge this daunting, it will very likely take more than one answer. One of the best we have, fyi, is information.  We know a huge amount about how people get sick, but more importantly, how to keep them from becoming ill in the first place.  And these days, an ounce of prevention could be worth about a million pounds of cure.

If the power of all the information from mountains of claims could be harnessed and packaged into wellness programs that people take to heart, we just might keep many of them from becoming patients.

Of course, getting folks to exercise regularly, eat their veggies and meditate is not going to wipe out diabetes, heart disease and cancer.  But it would definitely slow down the advance of these ailments to less than supersonic speeds, too.  And that's some information that could benefit us all.

You might consider incorporating some health information or programs into your marketing efforts. It could well benefit you.

February 29, 2008

Trust and Healthcare

jimp

I am currently reading The Trust Prescription for Healthcare.   In this book, David Shore, an associate dean at the Harvard School of Public Health, outlines the importance of trust for the healthcare consumer.  He discusses how the concept of trust is important not only in the physician-patient relationship, but also in the relationships held between patients and healthcare organizations. 

The Trust Prescription for Healthcare bookI like the first sentence of Shore's book:  "Trust is the currency of all commerce."  It is.

There are many studies that show that consumers are more likely to do business with companies that they trust.  And you need only to read any one of Thomas Friedman's books to see how a lack of trust (often brought on by corruption) has kept many countries from realizing their commercial potential.

But the relationship between trust and healthcare is unique.  As a patient, trust is vitally important because we are extremely vulnerable when we engage with the players in the healthcare system.  We rely on the intelligence, training and good judgment of others to provide advice, keep us healthy, and get us better when we become ill or require treatment.

In that regard, we often have vivid memories of the times where trust has been violated.  I can think of two examples in particular from my life where trust in a clinician was compromised. 

The first example revolved around my childhood dentist.  He was a big guy, probably in his early 50s.  He had a good demeanor and always asked me about school and sports.  But he had horrible teeth and bad breath.  I was only about ten years old at the time, but still savvy enough to think to myself "should I really listen to a guy about dental care if he doesn't seem to practice good oral hygiene himself?"

The second example revolves around a General Practitioner of mine.  During my annual physical, I was going over a list of questions I had written down about my general health - should I worry about this mole? What about my family's history of heart disease?, etc.   After each question he gave what I considered an intelligent, reasoned response. 

After one question, though, his reaction was very different.  He said to me in an extremely condescending tone "Why are you asking me that?  I'm not the person to talk to about that - you would need a specialist for that."  I won't divulge what my question was (for fear of committing my own, personal HIPAA violation), but he certainly should have addressed my question, and in a much more patient-friendly tone.

Back to the concept of trust and commerce.  As a ten year old boy, I had little influence on what dentist our family went to.  But as an adult living in one of the most respected healthcare environments in the world, I certainly had the power to reduce the ranks of this guy's practice.  Not only did I find a new doctor, but a friend of mine stopped seeing him based at least in part on hearing my story.

I would give David Shore's book a try.  The public's trust in medicine has decreased tremendously in the last forty years and this has a wide-ranging implications for those of us that work in, or for, healthcare-related organizations. 

And while the idea that trust as a crucial element of healthcare is not novel, I think the power of this book relies on the depth of knowledge that Shore brings to this topic as well as the real world examples he provides.  And I am sure that, like me, soon after you begin reading this book you will begin to revisit those positive and negative experiences you have had in dealing with the healthcare system.

October 15, 2007

The Vioxx Moment

Ed Feather

Patrick Clinton, Editor-in-Chief of Pharmaceutical Executive magazine, uses the terms “the Vioxx moment” and “the Avandia moment” in his September 2007 “From the Editor” column. He describes these as “the moment when a safety signal has been detected on a drug, and no one yet knows for certain whether it is real or not – the moment when pharma companies and FDA alike set themselves up for a kick in the teeth.”  In other words, do we tell people that someone died while taking our drug, or should we wait to see if anyone else dies?

Obviously, when a drug makes the body more likely to have a heart attack, disclosure is imperative – up front – so patients and doctors can discuss and weigh the risks of drugs, disease and other life issues they already face.  Some drugs treat serious, life-threatening diseases, but also have potentially serious side effects.  For some patients these drugs should never be used.  For others, those same drugs are a godsend because the patient would otherwise have had no chance at all of survival.

I worked with GSK a number of years ago to market Avandia, a drug that treats certain symptoms of type 2 diabetes. We were very careful to include all of the important risk information in the marketing pieces we created.  Our direct mail packages were large fulfillment mailers designed to provide patients with more information about Avandia, including all of the FDA-approved important safety information – with several points about heart failure as a possible side effect.

At the time, I felt very good about marketing a product like Avandia, because I believed that it was providing a vital benefit to many people with type 2 diabetes who could not control their blood sugar through other options.  Today, after the addition of a black-box warning to the Avandia packaging, I still believe that the drug is right for some patients and not right for others.  As always, that is for the doctors to decide.

As marketers, it is our responsibility to ensure we do everything we can to be truthful. While the goal is to sell more product, it should not be at the cost of public faith in medicine, nor at the cost of lives.  We must ensure that we include ALL of the safety information in a clear format that everyone can understand.

Print and online media generally afford the space for longer disclosures of safety information.  But with TV we may find ourselves foolishly searching for ways to shorten the fair balance while staying within FDA regulations.  In the end, if the safety information is not clear, and someone misses an important, life-changing piece of information, you have failed.

My advice: stick with integrity.  Do it right the first time.  Continue to elevate a positive profile for the pharmaceutical industry.  And help healthcare providers, and their patients, make the right medical decisions based on ALL of the necessary information.

September 21, 2007

A New Approach to Medical Errors

jimp

A recent editorial in the Boston Globe points out an interesting dynamic created by the Federal Government's new stance on penalizing hospitals for medical mistakes.  The Medicare Against Mistakes article underlines that "The new policy may require refinement, but it puts US hospitals on notice that they have got to work harder to make sure patients do not suffer needless harm while under their care."

The article discusses recent legislation that requires the Centers for Medicare and Medicaid Services to rule that Medicare will no longer pay for mistakes that are clearly a hospital's fault. It is no secret that medical errors carry tremendous costs to the healthcare system.  In fact, a conservative estimate of the financial impact of medical errors is $3.5B per year.

One of the most common and troubling medical errors discussed in the article is hospital-acquired infections.
The severity of this specific medical error is alarming.

Continue reading "A New Approach to Medical Errors" »

August 22, 2007

Making Medical Marketing a Little Easier to Understand

Ed Feather

According to the PEW Internet & American Life Project 80% of American Internet users have searched for health information on the web.  Most start at a general search engine to find health information, but eventually narrow their search to a health portal or a disease specific site.  Finding health information on the web is easy, but finding the RIGHT information, and information that can be trusted or easily understood is another story.

According to the American Academy of Physicians (AAP) there are now more than 24,000 medications on the market, and many have Websites with reams of product and disease information.  Combine this with the many health portals such as WebMD.com, CDC.gov and MayoClinic.com, and consumers often have more information than they can handle.  This means drug marketers need to be more and more careful about the information they provide online and how it is presented.  Is it enough?  Is it too much?  Is it easy for the target audience to find the Website, read the information and to understand it?

Continue reading "Making Medical Marketing a Little Easier to Understand" »

March 23, 2007

Reaching the Broadening List of Decision Makers

kara

As a general rule of thumb the more complex the technology and the more expensive the investment, the more players that are involved in the decision making process.  Not many companies empower one person (or even department) with exclusive decision and purchasing authority.

What does this mean for marketers who are trying to influence this long and complex decision?  First, you need to understand the people involved in the decision and each of their roles’ in the process.  Talk to your sales team, talk to your customers, utilize syndicated research (Marketing Sherpa’s Business Technology Marketing Benchmark is a great resource), sponsor a brief survey…find out what your up against, find out what makes them tick. 

For example:

  • Senior staff may be charged with the brunt of the groundwork – researching the solutions available to solve their problem.  How do the solutions interact with legacy systems?  These folks may be more impressed with the technology than others.  They want to understand how your solution will improve their life (and I don’t mean personal life)…
  • The CIO on the other hand, will be more concerned with how the solution advances the business goals of the organization.  Marketing Sherpa notes that in many cases they’ve seen the CIO come in at the last minute and often overrules a senior staffers recommendation.

Once you understand who they are, then you can develop targeted communications that address each of their individual needs.  This can mean slight tweaks in messaging as well as the offer.  Test and refine, test and refine.

Increasing awareness across all individuals involved in the decision making process (combined with a solid solution) will increase your sales. Try encouraging dialogue between the involved parties – incorporate refer a colleague functionality in to your communications.  Give the decision makers and influencers something to talk about.

And test and refine, test and refine.

February 27, 2007

The Art in Handling Healthcare Quality Data

Tom Simons

Paul Levy (Beth Israel Deaconess Medical Center CEO) has made a bold move in publishing his hospital's Central Line Infection data. Not necessarily because the results represent evidence of best practices, but because this may be the first example in the region of using these numbers artfully.

His latest blog posting on the subject can be found at http://runningahospital.blogspot.com/2007/02/we-saved-one-persons-life-can-we-keep.html

While we know that this kind of hospital data will form the basis for a patient's comparative evaluation and purchase decision support at some point in the future, Levy's bold stroke will likely create a preemptive impression that BIDMC is fully forthcoming about such measures — and other hospitals are not. Whether this yields any real long term business benefit remains to be seen, of course. But as the sector becomes fully transparent  and healthcare data sets are published, compared and analyzed it will be fascinating to watch more examples of how the numbers are "used" to their best advantage. Therein a business strategy lurks somewhere.

PS -- Invoking Mr Levy's blog is somewhat self-referential as he had kind words to say about our Q4 Blue Cross Blue Shield of Massachusetts campaign. See what he had to say about "Isabel's Story" at http://runningahospital.blogspot.com/2006/11/isabels-story.html

February 05, 2007

Not Another Whitepaper...

kara

For the ultimate mind bend – here’s a special report on whitepapers?  Okay it’s called a “special report” but you and I know this is a whitepaper on whitepapers.  Does this signify a cosmic event? The end of the universe as the comedian Louis Black would lead you to believe because there’s a Starbucks on all four corners of an intersection?

No, it reinforces the value of whitepapers and the need to write a good one in order to stand out in the sea of whitepapers. They are valuable content in the technology industry – particularly when a prospect is in decision making or buying stages.  Here are three tips to help increase downloads, content, and pass along and separate your paper from the masses.

  1. A smart title. Keep it to the point (not funny or trite).  Try testing whitepapers names to see which receives more downloads.  Michael Stelzner author of the book “Writing Whitepapers: How to Capture Readers and Keep Them Engaged” and founder of www.whitepapersource.com suggests trying numbers in titles.  For example, “Ten things you need to know about compliance”.  The title is one of the most important factors on whether your paper is read, not an afterthought or something that should be left to a technical writer.
  2. Keep it short and relevant.  While a short whitepaper sounds like a contradiction, we all know how hard it is to find the time to read a 25-page paper.   Instead try 4-6 pages and make it’s direct and easy to scan online.
  3. Use key words. Using the right key words in your abstract/paper summary will help ensure your paper can be found via search engines and within your site.  You wrote this great content – you want it to be easy to find and determine whether it’s relevant for them.

Keep in mind that whitepapers are a valuable marketing tool and should be given the same attention and care that a high profile ad campaign warrants.


ART+science EMAIL

Enter your email to subscribe:

Refer blog to a friend or coworker:

RSS FEEDS

  • Subscribe via RSS 2.0 feedSubscribe via RSS 2.0 feed
  • Subscribe via Atom 1.0 feedSubscribe via Atom 1.0 feed
  • AddThis Feed Button

Del.icio.us Links